
























Breast cancer is a leading cause of women’s cancers, 
although a small fraction of men may also be affected 
[1]. In this context, tumor recurrence [2] is particularly 
lethal and in the advanced stages is associated with 
treatment failure, due to therapy resistance [3, 4]. As 
current treatment strategies often tend to be associated 
with serious side effects,  new  non-toxic  treatment stra- 
 
tegies would fulfil an unmet medical need. As a 
consequence, many translational scientists and cli-
nicians are actively involved in the search for novel 
natural products, including spices and herbs, that may 
have therapeutic value and confer patient benefit.  
 
Interestingly, several recent studies have suggested that 
Japanese green tea has anti-proliferative, anti-oxidant, 
anti-bacterial, and chemo-preventive effects [5, 6]. In 






















Matcha  green  tea  (MGT)  is  a natural product  that  is  currently used  as  a dietary  supplement  and may have
significant  anti‐cancer  properties.  However,  the  molecular  mechanism(s)  underpinning  its  potential  health
benefits remain largely unknown. Here, we used MCF7 cells (an ER(+) human breast cancer cell line) as a model
system,  to systematically dissect  the effects of MGT at the cellular  level, via  i) metabolic phenotyping and  ii)
unbiased proteomics analysis. Our results  indicate that MGT  is  indeed sufficient to  inhibit the propagation of
breast  cancer  stem  cells  (CSCs),  with  an  IC‐50  of  ~0.2  mg/ml,  in  tissue  culture.  Interestingly,  metabolic
phenotyping  revealed  that  treatment  with  MGT  is  sufficient  to  suppress  both  oxidative  mitochondrial
metabolism  (OXPHOS)  and  glycolytic  flux,  shifting  cancer  cells  towards  a  more  quiescent  metabolic  state.
Unbiased  label‐free proteomics analysis  identified  the specific mitochondrial proteins and glycolytic enzymes
that  were  down‐regulated  by  MGT  treatment.  Moreover,  to  discover  the  underlying  signalling  pathways
involved  in  this metabolic  shift, we  subjected  our  proteomics  data  sets  to  bio‐informatics  interrogation  via
Ingenuity Pathway Analysis  (IPA)  software. Our  results  indicate  that MGT  strongly affected mTOR  signalling,
specifically down‐regulating many components of the 40S ribosome. This raises  the  intriguing possibility that
MGT can be used as inhibitor of mTOR, instead of chemical compounds, such as rapamycin. In addition, other
key pathways were affected,  including  the anti‐oxidant  response, cell cycle  regulation, as well as  interleukin
signalling. Our  results  are  consistent with  the  idea  that MGT may have  significant  therapeutic potential, by
mediating the metabolic reprogramming of cancer cells.  
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direct support of this notion, it has been demonstrated 
that a key component of green tea, namely 
epigallocatechin-3-gallate, behaves as an anti-oxidant 
and shows anti-tumor effects against breast cancer cells 
[7, 8]. Green tea may also interact with other com-
ponents of the diet, including those natural products 
contained within soy and mushrooms [9, 10]. Con-
sumption of green tea could partially explain why 
Asian-American women show a decreased risk for 
developing breast cancer [11]. 
 
Recently, the therapeutic effects of green tea catechins 
on breast tumorigenesis were evaluated out using pre-
clinical models, as well as clinical trials [12-15]. 
Furthermore, a meta-analysis of epidemiological studies 
in 2006 suggested that green tea may lower the risk of 
developing colorectal cancer [16]. Recently, it was 
demonstrated that tea has other protective effects, such 
as reducing the risk of mortality from heart disease and 
stroke (cerebrovascular accident) [17].  
 
A subsequent study, using green tea supplements, 
supports the idea that green tea extracts could be used in 
the chemo-prevention of metachronous colorectal 
adenomas, in Korean patients [18] (ClinicalTrials.gov, 
number NCT02321969). Finally, green tea has shown 
positive benefits in reducing Acute Myeloid Leukaemia 
(AML) risk [19] and prostate cancer [20]. Taken 
together, these studies suggest that green tea or its com-
ponents, may be very useful as anti-cancer agents.  
 
Several published preliminary studies in breast cancer 
have also been conducted, to evaluate the mechanism of 
action of green tea components. A broad-spectrum of 
different mechanism(s) has been described. For exam-
ple, these data suggest that green tea components 
display the following regulatory properties: i) anti-
angiogenic effects, mediated  through  the  inhibition  of  


















effects, mediated by inhibiting the infiltration of Tumor-
Associated Macrophages and the secretion of IL-6 and 
TNF-α [22]; iii) as well as the up-regulation of 
apoptosis and the down-regulation of cell proliferation 
[23], among others.  
 
Here, we investigated the potential therapeutic effects of 
Matcha green tea (MGT), a natural product, on the 
propagation of breast cancer stem cells, by using MCF7 
cells as a model system. Our results indicate that MGT 
effectively inhibits the propagation of CSCs, as measur-
ed using the mammosphere assay, with an IC-50 of 0.2 
mg/ml. Importantly, previous studies have clearly 
demonstrated that CSCs are involved in mediating 
tumor recurrence, distant metastasis and therapy failure 
due to chemo- and radio-resistance [24-26].  
 
In this report, we focused on following the metabolic 
effects of MGT on breast cancer cells, by using the 
Seahorse XFe96 Analyzer, to quantitatively measure 
metabolic flux. Our results directly show that MGT 
reduces both mitochondrial metabolism, as well as 
glycolysis, maintaining cancer cells in a more meta-
bolically quiescent state. Unbiased proteomics analysis 
identified the mitochondrial proteins and glycolytic 
enzymes that were down-regulated by MGT treatment. 
Thus, MGT or its components, may possess significant 
anti-cancer activity, by mediating the metabolic re-




Here, to dissect the effects of MGT at the phenotypic 
cellular level, MCF7 cancer cells were treated in 
adherent conditions with 0.2 mg/ml MGT, starting 24 
hours after plating. MGT treatment showed only a slight 
effect on the cancer cells in monolayer, reducing 
viability of bulk cancer cells by 8% (Fig. 1A). Next, to 



















proliferation were  tested on MCF7  cells  in monolayer by SRB assay. Note  that MGT only  slightly  reduced viability of bulk
cancer cells by 8%. (B) Importantly, MGT inhibited the sphere‐forming ability of MCF7 cells by 50%. Bar graphs are shown as
the mean ± SEM; t‐test, two‐tailed test. **p < 0.005, ***p < 0.0001. 
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cells were cultured in low-attachment conditions in the 
presence or absence of MGT. After five days of culture, 
the ability of CSCs to survive and grow was evaluated 
by counting the number of mammospheres. Intriguing-
ly, MGT treatment inhibited the sphere-formation 
capacity of MCF7 cells by 50%, indicating that MGT 
halts the propagation of cancer stem cells (Fig. 1B).  
 
It is well known that the propagation of CSCs depends, 
at least partially, on increased mitochondrial biogenesis 
and metabolism [27, 28]. To evaluate a possible effect 
of MGT on cellular metabolic features, we employed 
the Seahorse XF Analyzer to measure oxygen 
consumption rate (OCR) and extracellular acidification 
rate (ECAR). Interestingly, a 72-hours treatment with 








































production in MCF7 breast cancer cells, as compared to 
untreated cells (Fig. 2). Moreover, MGT treated cells 
displayed a reduction of glycolytic rate and glycolytic 
capacity, the latter referred to as measurement of the 
maximal capacity of the cells to respond to a higher 
ATP demand (Fig. 3). 
 
Afterwards, quantitative proteomic analysis was 
performed on protein samples obtained from MCF7 
cells treated with MGT (0.2 mg/ml) or with vehicle 
alone (media). Noticeably, the mass spectrometry 
analysis validated the results obtained by Seahorse 
analysis. Indeed, data analysis demonstrated that the 
expression of 57 mitochondrial-related proteins as well 
as 6 glycolytic proteins were significantly down-








































Figure  2. MGT  treatment  reduces basal  respiration  and ATP production  in MCF7  cells. MCF7  cells were
seeded at  the density of six  thousands cells  in 96‐wells plates. After  twenty‐four hours,  filtered 0.2 mg/ml MGT was
added and incubated for seventy‐two hours. Oxygen consumption rate (OCR) was measured by Seahorse XF Analyser.
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Previously, we published that treatment of MCF7 cells 
with the antibiotic doxycycline significantly inhibited 





















































chondrial and glycolytic proteins, as assessed by 
proteomics analysis [29]. Thus, proteomics results of 






















































Figure 3. MGT  treatment  inhibits glycolysis of MCF7 cells. MCF7 cells were  seeded and  treated with MGT as
described  above.  Extracellular  consumption  rate  (ECAR)  was  assessed  by  Seahorse  XF  Analyser.  Top  panel:
representative trace; bottom panel: bar graph with OCR quantification. Importantly, the treatment significantly reduced
the glycolysis and  the glycolytic  capacity as  compared  to  control cells. Experiments were performed  in  triplicate,  six
repeats for each replicate. Bar graphs are shown as the mean ± SEM, t‐test, two‐tailed test. *p < 0.05. 
Figure 4.  Venn diagram of proteomics data of MGT‐treated MCF7 cells versus doxycycline‐treated MCF7
cells.  Proteomic  analysis  validates  the  metabolic  effects  of  MGT  on  breast  cancer  cells.  (A)  Venn  diagram  of
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proteomics results of MGT-treated MCF7 cells. Venn 






















































down-regulated proteins, eight were in common between 



























































www.aging‐us.com  1872  AGING 
down-regulated proteins, four were in common between  
the two datasets (Fig. 4). Intriguingly, MGT treatment 
potently induced the down-regulation of mitochondrial 
and glycolytic proteins, like doxycycline treatment 
(Table 1A and Table 1B). 
 
Additionally, proteomics data were subjected to a 
bioinformatic analysis with the Ingenuity Pathway 
Analysis (IPA) software to identify metabolic pathways 
affected by MGT treatment and deepen our under-
standing of the altered cellular pathways upon MGT 
treatment. Fig. 5 depicts the main pathways altered by 





One of the pathways mostly altered by MGT treatment 
is the mTOR signaling pathway, a key regulator of 
cellular metabolism. Fig. 6 and Supplementary Table S1 
show indeed that several genes in the mTOR pathway 
are differentially expressed in MGT-treated cells 
compared to control cells. Notably, MGT treatment 
induces a relevant decrease in numerous proteins of the 
small ribosomal subunit 40S, with a likely compensato-
ry up-regulation of eukaryotic translation initiation 





























synthesis. Moreover, PPP2R5C, a key player in cell 
proliferation, differentiation, and transformation [30, 
31], is infinitely down-regulated. PPP2R5C is a regula-
tory B subunit of protein phosphatase 2A (PP2A), which 
is one of the main serine-threonine phosphatases in 
mammalian cells, and it maintains cell homeostasis by 
counteracting most of the kinase-driven intracellular sig-
naling pathways [32]. Consistent with infinite PPP2R5C 
down-regulation, our findings demonstrate inhibition of 
CSCs proliferation upon treatment with MGT. 
 
We have shown above that MGT treatment of MCF7 
cells decreased mitochondrial respiration, resulting in a 
reduced basal respiration and ATP production, as well 
as glycolysis and glycolytic capacity (Figs. 3 and 4). 
Consistently, IPA analysis confirmed the down-
regulation of several proteins involved in all oxidative 
phosphorylation complexes (Fig. 7). In particular, cyto-
chrome c, which plays a central role in the electron 
transport chain in the mitochondria, was infinitely 
down-regulated (Supplementary Table S2). Complex III 
is particularly affected by the treatment with MGT (Fig. 
7). These results are consistent with recently published 
study from our group, showing that the anti-malaria 
drug atovaquone, which specifically inhibits mito-
chondrial complex III, halts the propagation of MCF7-
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enzymes in the tricarboxylic acid cycle (TCA) 
(Supplementary Table S3) and in the mitochondrial 
dysfunction pathway were found altered (Supplementary 
Table S4), with a distinct up-regulation of complex V 
subunits, very likely a compensatory mechanism in 
response to the MGT-induced inhibition of complex III. 
Altogether, these data strongly suggest that MGT impairs 
mitochondrial respiration in MCF7 breast cancer cells. 
 
IPA analysis also revealed significant alterations in the 
glycolytic pathway (Fig. 8 and Supplementary Table 
S5). Notably, the expression of some enzymes involved 
in the initial preparatory phase of glycolysis (glucose 










































by MGT treatment. Indeed, enzymes that catalyze 
reversible reactions, such as aldolase and phospho-
glucose isomerase, are up-regulated as compared to 
untreated cells. However, fructose-bisphosphatase 1 and 
2 (FBP1 and 2) are up-regulated by 16 fold after MGT 
treatment. FBP is a key enzyme of gluconeogenesis, 
catalyzing the conversion from fructose 1,6- bisphos-
phate to fructose 6-phosphate, the opposite reaction of 
phosphofructokinase (PFK), the key regulatory and 
irreversible step of glycolysis, suggesting that glyco-
lysis might be blocked at the PFK step in MGT-treated 
cells. Indeed, two PFK isoforms (PFKL and PFKP) are 
significantly down-regulated after MGT treatment 












































Figure  6.  IPA  analysis:  Schematic  representation  of mTOR  pathway.  IPA  analysis  revealed  changes  in  the
expression of proteins involved in mTOR signalling after MGT treatment for 48 hours. In this map, the 40S ribosome was
indicated as dramatically down‐regulated (intense green colour), suggesting likely inhibition of protein translation.  






























Consistent with this notion, some glycolytic enzymes 
were dramatically down-regulated by MGT treatment. 
Phosphoglycerate mutase expression was decreased by 
250 fold. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), which catalyzes the conversion of 
glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate, 
was infinitely down-regulated in MGT-treated cells. 
Importantly, it was previously shown that vitamin C 
selectively and potently inhibits glycolysis by targeting 
GAPDH [34]. We have also shown that vitamin C halts 
the propagation of highly glycolytic doxycycline-
resistant CSCs [35]. Thus, the current results suggest 
the intriguing possibility that MGT might similarly act 
as a glycolysis inhibitor, via GAPDH inhibition. More-
over, IPA analysis suggests that there was no pro-
duction of lactate from pyruvate since key enzymes 
involved in the fermentation of pyruvate to lactate were 
remarkably down-regulated (Supplementary Table 5S). 
Altogether with the functional data of Seahorse 
analysis, these results suggest that MGT effectively 
inhibits the glycolytic pathway. 
 
Interestingly, the Pentose Phosphate Pathway (PPP) is 
activated (Fig. 9 and Supplementary Table S6). Tea 
cathechins may act both as anti-oxidant and as pro-
oxidants [36]. As a consequence, upon exposure to 






























antioxidant cofactor NADPH. In the cytosol, NADPH is 
normally reduced from NADP+ during the PPP 
oxidative phase, which serves as a major source of 
NADPH. Indeed, Supplementary Table S6 shows that 
the 3 key enzymes of the PPP oxidative phase are 
upregulated by MGT treatment. MGT causes decreased 
expression of GAPDH (Supplementary Table S5), 
likely re-routing the metabolic flux from glycolysis to 
PPP, to allow the cells to generate more NADPH.  
 
Finally, MGT-treated cells display an increase in the 
beta-oxidation pathway (Supplementary Table S7), 
most likely in an attempt to compensate for the 
decreased mitochondrial respiration and glycolysis. In 
fact, several enzyme involved in beta-oxidation are 
elevated, including ECHS1 (enoyl-CoA hydratase), 
HADH (Hydroxyacyl-CoA dehydrogenase), ACAA 
(acetyl-CoA acyltransferase), respectively catalyzing 
the second, third, and fourth step of beta-oxidation. 
Consistent with an increase in beta-oxidation, the 
enzymes involved in the Acetyl-CoA biosynthesis (Sup-
plementary Table S8-A) are also increased. Moreover, 
Supplementary Table S8-B shows that BDH1 (3-
hydroxybutyrate dehydrogenase) expression is 
remarkably increased after MGT treatment. Upon fatty 
acid degradation, large amounts of acetyl-CoA are 
generated and in the absence of functional mitochon-
Figure  7.  Impairment  of  mitochondrial  functions  uncovered  by  IPA  analysis.  Depicted  is  the  map  of  oxidative
phosphorylation. All  the mitochondrial complexes are affected by  the  treatment, particularly complex  III  is dramatically down‐
regulated, as indicated by the intense green colour. 
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drial metabolism, acetyl-CoA maybe converted to beta-
hydroxybutyrate in a 3-step pathway that critically 
involves BDH1. Importantly, beta-hydroxyburyrate is 




















































38]. Note that lipid synthesis pathway is likely 
inhibited, given that one of the most important enzyme, 
i.e. fatty acid synthase (FASN) was infinitely down-


















































































Cell cycle regulation 
 
IPA analysis of our proteomics data detected alterations 
in cell cycle regulation after treatment with MGT (Fig. 
10 and Supplementary Table S10). The p53 tumour 
suppressor protein, which is a transcription factor 
stabilized and activated in response to a range of cellu-
lar stresses including hyper-proliferation, DNA damage 
and shortage of glucose, was significantly up-regulated 
(by 5.9 fold) as compared to untreated cells (Sup-
plementary Table S10). Phosphorylation of p53 
necessary for its activation occurs normally by the 
action of two proteins, namely ATM and ATR protein 
kinases. Supplementary Table S10 shows that the ATR 
protein kinase is infinitely up-regulated. This finding 
suggests that MGT may promote a p53-induced cell-
cycle arrest or programmed cell death. Furthermore, the 
tumor suppressor retinoblastoma protein (RB1) is 
significantly up-regulated by MGT treatment, likely 
inhibiting cell cycle progression (Supplementary Table 
S10). In addition, it is well known that the RB1 attracts 
histone deacetylase 1 (HDAC1) to the chromatin, 
reducing transcription of S-phase promoting factors, 
further suppressing DNA synthesis [39]. Consistent 
with this notion, Supplementary Table S10 shows the 
up-regulation HDAC1, upon  MGT  treatment.  Cyclins/ 
CDKs-mediated hyper-phosphorylation of RB1 serves 
to inactivate RB1, allowing cell cycle progression. 
Interestingly, MGT treatment reduces the levels of 
cyclins/CDKs, presumably activating RB1 and hinder-


























S10). Lastly, MGT treatment down-regulates by 18-fold 
SKP1 (S-phase kinase-associated protein 1), a protein 
involved in the ubiquitination of cell cycle proteins 
(Supplementary Table S10). Although the role of this 
protein during tumorigenesis remains unclear, it is 
known that SKP complex targets CDK inhibitor p27 for 
degradation [40] and it has been recently published that 
in non-small cell lung cancers elevated levels of SKP1 
was associated with poor prognosis [41]. Altogether, 
these data suggest that MGT inhibits cells cycle 
progression by up-regulation of p53 and RB1. These 
data are consistent with previously published findings 
showing that green tea polyphenols display anti-tumors 
activities of MCF7 cells, by inducing cell cycle arrest 




This study demonstrates that treatment with MGT up-
regulates the enzymes of the oxidative branch of the 
pentose phosphate pathway, which is responsible for the 
production of the antioxidant NADPH (Fig. 9 and 
Supplementary Table S6). Moreover, IPA analysis 
revealed that several proteins implicated in the NRF2-
stress-related pathway were significantly altered 
(Supplementary Table S11). In particular, note the in-
crease of glutathione S transferases, enzymes involved 
in detoxification processes. Similarly, catalase, thiore-
doxin, NQO1 and superoxide dismutase, which all play 
important roles in anti-oxidant responses [43, 44], were 
all found up-regulated after MGT treatment. 
Figure 9. Changes in the expression of proteins implicated in the pentose phosphate pathway. MGT treatment up‐
regulates the expression of proteins involved in the PPP pathway (red colour).  













































IPA analysis showed that treatment with MGT affected 
the IL-8 pathway. IL-8 signaling is involved in 
angiogenesis, proliferation and increment of the 
migratory capacity of cancer cells. A decrease in the 
expression of most of the proteins involved in the 
pathway is observed after MGT treatment (Supplemen-
tary Table S12). Interestingly, VCAM 1 and the 
transcription factor NF-kB (encoded by the RELA 
gene) are both down-regulated. NF-kB is implicated in 
many cellular processes, including inflammation, 
metabolism and chemotaxis, and VCAM 1 mediates 











































findings suggest that MGT may inhibit: i) IL-8-
mediated induction of VCAM1 by blocking ERK1/2 
(note that many MAPKs are down-regulated); and ii) 
NF-kB signaling pathway, leading to a reduction of the 
inflammatory process, invasion and metastasis.  
 
Moreover, the IPA analysis suggests an impairment of 
the PI3K/Akt signaling pathway. Note that PIK3C2B (a 
PI3K family member) is down-regulated by 8.49 fold, 
likely leading to impaired phosphorylation and 
activation of AKT and promoting pro-apoptotic events. 
Consistent with this notion, the expression of the 



































Over the past years, the anti-cancer properties of green 
tea or its components have been investigated. Its effect-
tiveness is reported across several types of tumor. 
Importantly, previous studies have reported that green 
tea and epigallocatechin gallate (EGCG), one of the 
main components of green tea, suppresses cancer stem-
like cells (CSCs) properties in a variety of cellular 
models [46-48]. Here, we aimed to investigate if the 
inhibitory efficacy of MGT on CSCs is associated with 
inhibition of cellular metabolism. The results presented 
in this paper demonstrate that MGT preferentially 
inhibits CSC proliferative expansion derived from 
MCF7 breast cancer cells. Furthermore, MGT treatment 
overall reduced cellular metabolism, including mito-
chondrial respiration and glycolysis, as assessed by 
Seahorse analysis. These phenotypic results were 
integrated with proteomic analysis data obtained from 
MGT-treated cells. Bioinformatics analysis through 
Ingenuity Pathway Analysis (IPA) showed that MGT 
not only affected mitochondrial respiration and 
glycolysis, but also fatty acid synthesis, validating 
results already described in the literature. It has been 































several hepatic enzymes, including fatty acid synthase 
(FASN) [49]. FASN is an enzyme overexpressed in 
many cancer types that plays a key role in tumori-
genesis [50]. Consistently, our results demonstrate that 
MGT treatment dramatically decreased FASN expres-
sion, as compared to control cells. Furthermore, we also 
found that gluconeogenesis was down-regulated by 
MGT treatment, concordantly with in vivo and in vitro 
results on human colon carcinoma Caco-2 cells treated 
with EGCG [51]. The metabolic changes observed in 
MCF7 upon treatment with MGT are summarized in 
Fig. 11. 
 
IPA analysis indicates that MGT may have broad and 
profound effects on a variety of cellular processes. 
Indeed, our findings suggest that MGT may affect cell 
cycle progression and the oxidative stress response in 
MCF7 cells. These effects have been already described 
in different cancer types [52, 53]. Furthermore, MGT 
treatment may decrease inflammation and angiogenesis, 
as well as may inhibit the mTOR pathway (target of 
rapamycin), impairing protein synthesis. This raises the 
intriguing possibility that the natural compound MGT 
can be used as inhibitor of mTOR, instead of chemical 
compounds, such as rapamycin. 
Figure 11. Overview of  the metabolic and  cellular processes affected by MGT. Note  that MGT
treatment  inhibits  cellular metabolism  (glycolysis, mitochondrial  respiration,  fatty  acid  synthesis) with  a
likely compensatory increase in fatty acid breakdown.  
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Lastly, analysis of our proteomic data revealed that 
MGT displays overlapping effects in targeting 
mitochondria with the antibiotic doxycycline. Thus, the 
natural compound MGT may help prevent tumor recur-
rence and metastases, reducing the side effects of the 
anti-cancer therapy, similarly to what has been proposed 




In summary, we found that the natural compound 
Matcha green tea mechanistically targets oxidative 
phosphorylation and therefore CSC propagation. 
Importantly, we demonstrated that MGT effectively 
down-regulated oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR). Moreover, 
MGT treatment impaired others cellular metabolic 
pathways, and several cell signaling pathways such as 
cell cycle regulation, antioxidant response and inflam-
mation. Altogether, these findings strongly propose 
MGT as a natural compound that may help to overcome 
cancer cell resistance to chemotherapy. Surely, more 
molecular studies and clinical trials are warranted. 
 




MCF7 were purchased from ATCC. Media for cell 
cultures was DMEM (D6546, Sigma-Aldrich). Cell 
culture media (DMEM/F12) for spheroid culture was 
purchased from Life Technologies. Sulforhodamine B 
(SRB), 1x Trypsin-EDTA, 2-hydroxyethylmethacrylate 
(poly-HEMA) were purchased from Sigma-Aldrich. 
Matcha green tea (MGT) powder was a generous gift 
from OMGTea, Inc. (UK).  The exact chemical compo-
sition of the product is available upon request from the 
manufacturer [Contact Katherine Swift (Founder, 




A single cell suspension was prepared using enzymatic 
(1x Trypsin-EDTA) and manual disaggregation (25 
gauge needle) [55]. Five thousand cells were plated 
with spheroids medium (DMEM-F12/B27/EGF-
20ng/ml/PenStrep), in non-adherent conditions, in six 
wells plates coated with poly-HEMA. After five days of 
culture, the number of spheres with diameter >50 µm 




Extracellular acidification rates (ECAR) and oxygen 
consumption rates (OCR) were analysed using the 
Seahorse XFe96 bioenergetic analyser (Seahorse 
Bioscience, MA, USA). Six thousand MCF7 cells were 
seeded per well, into XF96-well cell culture plates, and 
incubated at 37°C in a 5% CO2 humidified atmosphere. 
MCF7 cells were maintained in DMEM supplemented 
with 10% FBS (Fetal Bovine Serum), 2 mM GlutaMAX, 
and 1% Pen- Strep.  Twenty-four hours from the plating, 
cells were incubated with/without filtered MGT at the 
concentration of 0.2 mg/ml (dissolved in water). After 
seventy-two hours, cells were washed in pre-warmed XF 
assay media as previously described [56]. ECAR and 
OCR measurements were normalized by cellular protein 
content (SRB). Data set was analyzed by XFe-96 
software and Excel software, using Student’s t-test 
calculations. All experiments were performed in 




Cells were subjected to SRB colorimetric assay for 
cytotoxicity, based on the measurement of cellular 
protein content. Briefly, MCF7 cells in monolayers 
were first fixed with 10% trichloroacetic acid and then 
washed with 1% acetic acid. The OD determination at 
510 nm using a microplate reader was done after the 
dye dissolution in 10mMTris base solution [57]. 
 
Quantitative proteomic analysis 
 
Cell lysates, obtained after treatment with MGT for 48 
hours, were subjected to quantitative proteomic analysis 
as previously described [29]. Data were analyzed using 
the Mascot search engine. Five technical replicates were 
made for each sample (untreated and MGT-treated cells). 
Statistical analyses were performed using ANOVA and 
only fold-changes in proteins greater than 1.2, with a p-
value less than 0.05 were considered significant.  
 
Ingenuity pathway analyses 
 
Ingenuity Pathway Analysis (IPA) (Ingenuity systems, 
http://www.ingenuity.com) was employed to analyze 
pathways and functions in the proteomics datasets. IPA 
aids the interpretation of the proteomics data, by 
organizing differentially expressed proteins into noted 




All data are presented as means ± SEM. Student’s t test 
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